Cardiac Reverse Remodeling as a Mechanism for the Cardioprotective Benefits Offered by Sodium-Glucose Cotransporter 2 Inhibitors
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated a marked ability to reduce the occurrence of adverse cardiovascular and heart failure events across a wide variety of patient populations. These benefits have been reported in patients with pre-existing heart failure, as well as in patients without prior documented heart failure who have risk factors. The profound clinical benefits associated with SGLT2i have sparked significant interest in elucidating the underlying mechanism(s) responsible for how SGLT2i delay the development and progression of heart failure. One postulated mechanism with merit involves the SGLT2i-mediated reversal of adverse cardiac remodeling. Within the current thesis, we aimed to investigate the mechanism responsible for the cardiac benefits associated with SGLT2i, to understand whether 6-month treatment with empagliflozin promoted cardiac reverse remodeling in patients without prevalent heart failure but who had risk factors. We also aimed to assess underlying factors that could influence the degree of benefit derived from SGLT2i treatment in relation to cardiac reverse remodeling. All assessments of cardiac structure and function in our studies were performed using gold-standard cardiac magnetic resonance imaging. We reported that (1) in patients with diabetes and coronary artery disease, those with an increased left ventricular mass indexed to body surface area (LVMi) at baseline experienced greater LVMi regression with…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.